8 results
Management of patients with known or suspected malignant pleural effusion (MPE) - An Official ATS/STS/STR Clinical
Management of patients ... known or suspected malignant ... ATS/STS/STR Clinical ... goals of assessing lung ... #Malignant #Pleural
COVID-19 on POCUS

I am infected with COVID-19. This is my own #POCUS 2 days after the
No feeling of dyspnea ... observed in the chest ... #POCUS #Clinical ... #Lung #Ultrasound ... #SARSCoV2 #Coronavirus
COVID-19 on Lung POCUS

Day 4 after COVID diagnosis. More cough & tiredness (very badly), still no
COVID-19 on Lung ... badly), still no dyspnea ... more thickened pleural ... #clinical #lung ... #ultrasound #pulmonary
Fibrinous septations in Malignant Pleural Effusion (MPE) - Lung POCUS
 • can be triggered by thoracenteses
Pleural Effusion ... (MPE) - Lung POCUS ... prospective e/o dyspnea ... #MPE #Lung #POCUS ... #clinical #ultrasound
Lung Abscess - Diagnosis and Management Summary

Lung Abscess Etiology:
 • Necrosis of lung parenchyma by a
Lung Abscess - Diagnosis ... Lung abscess ... Lung Abscess - Clinical ... pain, hemoptysis, dyspnea ... polyangiitis) • Malignancy
Management of patients with known or suspected malignant pleural effusion (MPE) - An Official ATS/STS/STR Clinical
Management of patients ... (MPE) - An Official ... ATS/STS/STR Clinical ... goals of assessing lung ... #Management #Pleural
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
abscess Primary ... characteristic features Clinical ... hemoptysis • Dyspnea ... organ system: • Pleura ... TB #Diagnosis #Management
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
abscess Primary ... characteristic features Clinical ... hemoptysis • Dyspnea ... organ system: • Pleura ... TB #Diagnosis #Management